Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile
Mainz Biomed - Stock

Mainz Biomed Stock

MYNZ
NL0015000LC2
A3C6XX

Price

0.39
Today +/-
+0
Today %
+0 %
P

Mainz Biomed Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Mainz Biomed, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Mainz Biomed from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Mainz Biomed’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Mainz Biomed. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Mainz Biomed’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Mainz Biomed’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Mainz Biomed’s growth potential.

Mainz Biomed Revenue, EBIT and net profit per share

DateMainz Biomed RevenueMainz Biomed EBITMainz Biomed Net Income
2029e181.16 M undefined0 undefined5.81 M undefined
2028e105.63 M undefined-4.76 M undefined-893,112 undefined
2027e45.7 M undefined-41.75 M undefined-6.92 M undefined
2026e13.25 M undefined-29.99 M undefined-11.95 M undefined
2025e4.36 M undefined-29.89 M undefined-14.18 M undefined
2024e1.5 M undefined-26.77 M undefined-17.79 M undefined
2023895,480 undefined-26.64 M undefined-26.3 M undefined
2022530,000 undefined-26.51 M undefined-26.39 M undefined
2021580,000 undefined-9.72 M undefined-11.69 M undefined
2020490,000 undefined-680,000 undefined-590,000 undefined
2019280,000 undefined-920,000 undefined-960,000 undefined

Mainz Biomed Stock Ratios

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201920202021202220232024e2025e2026e2027e2028e2029e
00000141345105181
------300.00225.00246.15133.3372.38
-----------
00000000000
00-9-26-26-26-29-29-41-40
------2,600.00-725.00-223.08-91.11-3.81-
00-11-26-26-17-14-11-605
---136.36--34.62-17.65-21.43-45.45--
13.5113.5113.9614.1616.24000000
- - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Mainz Biomed Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Mainz Biomed is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Mainz Biomed provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Mainz Biomed's financial health and stability.

Assets

Mainz Biomed's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Mainz Biomed must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Mainz Biomed after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Mainz Biomed's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (k)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (k)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2019202020212022
00-11-26
0000
0000
0001,000
0089
0000
0000
00-3-14
0000
001,0000
001,0000
0000
0000
001024
001023
----
0000
0088
-0.42-0.48-3.24-15.43
0000

Mainz Biomed stock margins

The Mainz Biomed margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mainz Biomed. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mainz Biomed.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Mainz Biomed's sales revenue. A higher gross margin percentage indicates that the Mainz Biomed retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Mainz Biomed's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Mainz Biomed's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Mainz Biomed's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Mainz Biomed. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Mainz Biomed's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Mainz Biomed Margin History

Mainz Biomed Gross marginMainz Biomed Profit marginMainz Biomed EBIT marginMainz Biomed Profit margin
2029e56.91 %0 %3.2 %
2028e56.91 %-4.51 %-0.85 %
2027e56.91 %-91.35 %-15.14 %
2026e56.91 %-226.39 %-90.18 %
2025e56.91 %-684.83 %-324.89 %
2024e56.91 %-1,785.68 %-1,186.65 %
202356.91 %-2,975.46 %-2,936.5 %
202233.96 %-5,001.89 %-4,979.25 %
202131.03 %-1,675.86 %-2,015.52 %
202024.49 %-138.78 %-120.41 %
2019-21.43 %-328.57 %-342.86 %

Mainz Biomed Stock Sales Revenue, EBIT, Earnings per Share

The Mainz Biomed earnings per share therefore indicates how much revenue Mainz Biomed has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Mainz Biomed earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Mainz Biomed's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Mainz Biomed’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Mainz Biomed's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Mainz Biomed Revenue, EBIT and net profit per share

DateMainz Biomed Sales per ShareMainz Biomed EBIT per shareMainz Biomed Earnings per Share
2029e8.28 undefined0 undefined0.27 undefined
2028e4.83 undefined0 undefined-0.04 undefined
2027e2.09 undefined0 undefined-0.32 undefined
2026e0.61 undefined0 undefined-0.55 undefined
2025e0.2 undefined0 undefined-0.65 undefined
2024e0.07 undefined0 undefined-0.81 undefined
20230.06 undefined-1.64 undefined-1.62 undefined
20220.04 undefined-1.87 undefined-1.86 undefined
20210.04 undefined-0.7 undefined-0.84 undefined
20200.04 undefined-0.05 undefined-0.04 undefined
20190.02 undefined-0.07 undefined-0.07 undefined

Mainz Biomed business model

Mainz Biomed is one of the most popular companies on Eulerpool.com.

Mainz Biomed valuation based on historical P/E ratio, EBIT, and P/S ratio.

Mainz Biomed shares outstanding

The number of shares was Mainz Biomed in 2023 — This indicates how many shares 16.242 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Mainz Biomed earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Mainz Biomed's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Mainz Biomed’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Mainz Biomed's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Mainz Biomed.

Mainz Biomed Earnings Surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-0.22 -0.24  (-9.44 %)2024 Q1
12/31/2023-0.32 -0.24  (25.7 %)2023 Q4
9/30/2023-0.48 -0.39  (19.22 %)2023 Q3
6/30/2023-0.43 -0.56  (-30.72 %)2023 Q2
3/31/2023-0.44 -0.45  (-3.4 %)2023 Q1
1

Mainz Biomed Stock Shareholders

%
Name
Stocks
Change
Date
5.65 % Fur Wiederaufbau (Kredianstalt)1,237,501012/31/2023
5.12 % Hekland (Hans)1,121,427300,0004/4/2023
4.07 % Eidens (Moritz)890,652-116,9634/4/2023
1.16 % Baechler (Guido)254,50704/4/2023
0.58 % Freese (Philipp)126,27604/4/2023
0.34 % Prelude Capital Management, LLC75,00075,00012/31/2023
0.15 % Citadel Advisors LLC33,24433,24412/31/2023
0.15 % Morgan Stanley & Co. LLC31,84531,84512/31/2023
0.08 % Northern Trust Global Investments Limited16,54116,54112/31/2023
0.08 % Northern Trust Investments, Inc.16,54116,54112/31/2023
1
2
3

Mainz Biomed stock: Frequently Asked Questions

What is the P/E ratio of Mainz Biomed 2024?

The Mainz Biomed P/E ratio is -0.35.

What is the P/S ratio of Mainz Biomed 2024?

The Mainz Biomed P/S ratio is 4.2.

What is the AlleAktien quality score of Mainz Biomed?

The AlleAktien quality score for Mainz Biomed is 4/10.

What is the revenue of Mainz Biomed 2024?

The expected Mainz Biomed revenue is 1.5 M USD.

How high is the profit of Mainz Biomed 2024?

The expected Mainz Biomed profit is -17.79 M USD.

What is the business model of Mainz Biomed

No history available for Mainz Biomed.

What is the Mainz Biomed dividend?

Mainz Biomed pays a dividend of 0 USD distributed over payouts per year.

How often does Mainz Biomed pay dividends?

The dividend cannot currently be calculated for Mainz Biomed or the company does not pay out a dividend.

What is the Mainz Biomed ISIN?

The ISIN of Mainz Biomed is NL0015000LC2.

What is the Mainz Biomed WKN?

The WKN of Mainz Biomed is A3C6XX.

What is the Mainz Biomed ticker?

The ticker of Mainz Biomed is MYNZ.

How much dividend does Mainz Biomed pay?

Over the past 12 months, Mainz Biomed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mainz Biomed is expected to pay a dividend of 0 USD.

What is the dividend yield of Mainz Biomed?

The current dividend yield of Mainz Biomed is .

When does Mainz Biomed pay dividends?

Mainz Biomed pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mainz Biomed?

Mainz Biomed paid dividends every year for the past 0 years.

What is the dividend of Mainz Biomed?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mainz Biomed located?

Mainz Biomed is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mainz Biomed kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mainz Biomed from 7/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/6/2024.

When did Mainz Biomed pay the last dividend?

The last dividend was paid out on 7/6/2024.

What was the dividend of Mainz Biomed in the year 2023?

In the year 2023, Mainz Biomed distributed 0 USD as dividends.

In which currency does Mainz Biomed pay out the dividend?

The dividends of Mainz Biomed are distributed in USD.

Other fundamentals and analyses of Mainz Biomed in the deep dive.

Our stock analysis for Mainz Biomed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mainz Biomed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.